BGNE News and Press, BeiGene Ltd. From 02/13/24

2024-02-13 12:58:23 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for ...

2024-02-07 11:28:54 ET More on I-Mab Biopharma Seeking Alpha’s Quant Rating on I-Mab Biopharma Historical earnings data for I-Mab Biopharma Financial information for I-Mab Biopharma Read the full article on Seeking Alpha For further details see...

Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma Canada NewsWire BRUKINSA is the first and only BTK inhibitor approved for follicular lymphoma in Canada Follicular lymphoma (FL) is the 2nd most com...

2024-02-06 10:04:54 ET Summary Zymeworks' share price is moving higher lately, led by an overall recovery of biotech stocks, and possibly by increased investor interest in the company’s emerging antibody-drug conjugate platform. The topline results from the phase 3 trial of...

A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) fell 5.0% to $11.72 on volume of 189,765,259 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 3.8% to $5.09 on volume of 143,664,257 shares Amazon.com Inc. (AMZN) rose 7.9% to $171.81 on volume of ...

A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) fell 5.5% to $11.665 on volume of 166,461,596 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 4.1% to $5.075 on volume of 129,958,072 shares Remark Holdings Inc. (MARK) rose 16.2% to $0.593899 on ...

A look at the top 10 most actives in the United States Connexa Sports Technologies Inc. (CNXA) rose 101.2% to $0.4 on volume of 236,162,112 shares PROSHARES TRUST (SQQQ) rose 5.9% to $12.78 on volume of 177,226,563 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 4.5% to $5....

2024-01-31 13:04:00 ET Summary ZYME's partners, JAZZ and BGNE, are potentially within a year of approval and launch of zanidatamab, a bispecific anti-HER2 antibody. The approval and launch of zanidatamab in multiple markets could generate significant milestones and royalty streams...

Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib) Canada NewsWire BRUKINSA is now listed on the RAMQ and ODB formularies. Two global Phase 3 trials in adults with CLL ...

2024-01-30 10:22:11 ET More on Arcus Biosciences Arcus Biosciences: Showing There Might Be Something To TIGIT After All Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey Arcus Biosciences, Inc. (RCUS) Q3 2023 Earnings Call Transcript Gilead invest...